핵의학

본문글자크기
  • [Neuroreport.] Clinical significance of visually equivocal amyloid PET findings from the Alzheimer's Disease Neuroimaging Initiative cohort.

    울산의대 / 오민영, 김재승*

  • 출처
    Neuroreport.
  • 등재일
    2018 May 2
  • 저널이슈번호
    29(7):553-558. doi: 10.1097/WNR.0000000000000986.
  • 내용

    바로가기  >

    Abstract
    To evaluate the clinical and imaging characteristics of patients with visually equivocal amyloid PET images, patients from the Alzheimer's Disease Neuroimaging Initiative cohort who had fluorine-18-florbetapir PET scans both at baseline and 24 months were selected. Five nuclear medicine physicians visually assessed the PET images and classified them as either positive or negative. Images not reaching a majority agreement were classified as equivocal. Among a total of 379 patients, the number of patients in each fluorine-18-florbetapir PET negative/equivocal/positive categories was 218 (57.5%), 32 (8.4%), and 129 (34.0%). Eight to 9% of patients with normal cognition (N=12/141), mild cognitive impairment (N=20/214), and no Alzheimer's disease (N=0/24) showed equivocal PET finding for each. In negative/equivocal/positive groups, positive cerebrospinal fluid Aβ1-42 was observed in 25.7, 81.5, and 98.3%, respectively. Baseline standardized uptake value ratios of fluorine-18-florbetapir PET were 0.75±0.05, 0.86±0.09, and 1.01±0.09, respectively [F(2, 376)=603.547; P<0.001]. After 24 months of follow-up, the standardized uptake value ratios increased by 0.81±2.62, 2.81±2.90, and 2.17±3.66%, respectively [F(2, 376)=7.905, P<0.05 vs. the negative group]. Among mild cognitive impairment patients, the equivocal group showed a more rapid decline in glucose metabolism than the negative group [5.52±5.36 vs. 0.67±4.45; F(2, 122)=9.028, P<0.01]. 8.4% of the patients in this study showed a visually equivocal result of amyloid PET. These patients showed a moderate amount of amyloid accumulation and a rapid rate of accumulation.

     


    Author information

    Oh M1, Seo M2, Oh SY3, Kim H4, Choi BW5, Oh JS1, Kim JS1; Alzheimer’s Disease Neuroimaging Initiative.
    1
    Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine.
    2
    Department of Nuclear Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan.
    3
    Department of Nuclear Medicine, National Police Hospital, Seoul.
    4
    Department of Nuclear Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan.
    5
    Department of Nuclear Medicine, Daegu Catholic University Medical Center, School of Medicine, Catholic University of Daegu, Daegu, Korea.

  • 편집위원

    Dementia에서 이용되고 있는 amyloid PET image는 환자 brain에amyloid deposit 유무와 정도를 평가할 수 있는 유용한 non-invasive method임. 그러나 equivocal case들이 적지 않게 나오며 이러한 경우 clinically challenging한 상황이 될 수 있는데, 이 연구에 data가 equivocal finding을 보이는 환자들의 diagnosis와 management 방향을 결정하는데 있어서 유용할 것으로 기대됨.

    2018-06-21 10:59:24

  • 덧글달기
    덧글달기
       IP : 3.145.63.136

    등록